These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Adriamycin, cisplatin, and etoposide combination chemotherapy for small cell lung cancer].
    Author: Irino S, Fujita J, Yamaji Y, Futami H, Hashimoto Y, Bungo M, Iuchi Y, Kamei M, Nakamura H, Hata Y.
    Journal: Gan To Kagaku Ryoho; 1989 Jun; 16(6):2263-7. PubMed ID: 2544150.
    Abstract:
    Twenty-three patients with small cell lung cancer (11 with limited disease and 12 with extensive disease) who had not received previous chemotherapy were treated with a combination of adriamycin (30 mg/m2, i.v., on day 1), cisplatin (80 mg/m2, i.v., on day 1) and etoposide (70 mg/m2, i.v., on day 1-5). This chemotherapy regimen was repeated at 3- or 4-week intervals for 3 to 5 treatment cycles. Among 22 evaluable patients, 5 showed complete response and 17 had a partial response (response rate 100%). The median response duration of 12 extensive disease patients was 21 months. There were 5 survivors for more than 2 years. Toxicity included moderate to severe hematologic toxicity, alopecia, nausea and vomiting. This combination chemotherapy appears to be optimal for the treatment of small cell lung cancer.
    [Abstract] [Full Text] [Related] [New Search]